Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

Multiple Sclerosis

Volumn 23, Issue 1, 2017, Pages 62-71

  Novakova, Lenka ^a   Axelsson, Markus ^a   Khademi, Mohsen ^a   Zetterberg, Henrik ^b   Blennow, Kaj ^b   Malmeström, Clas ^a   Piehl, Fredrik ^a   Olsson, Tomas ^a   Lycke, Jan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

biomarkers; cerebrospinal fluid; fingolimod; Multiple sclerosis; treatment response

Indexed keywords

BIOLOGICAL MARKER; CHITINASE 3 LIKE PROTEIN 1; CHITOTRIOSIDASE; CXCL13 CHEMOKINE; FINGOLIMOD; GLIAL FIBRILLARY ACIDIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NATALIZUMAB; NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; NEUROGRANIN; UNCLASSIFIED DRUG; BETA INTERFERON; GLATIRAMER; TERIFLUNOMIDE; CXCL13 PROTEIN, HUMAN; NEUROFILAMENT PROTEIN L;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; SPECTROFLUOROMETRY; TREATMENT DURATION; DEGENERATIVE DISEASE; DISEASE MARKER; PROTEIN CEREBROSPINAL FLUID LEVEL; CEREBROSPINAL FLUID; DISEASE EXACERBATION; INFLAMMATION; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BIOMARKERS; CHEMOKINE CXCL13; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FINGOLIMOD HYDROCHLORIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85011422827     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516639384     Document Type: Article

References (33)

1. Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010; 75: 403-410.
2. Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010; 176: 2682-2694.
3. Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 2012; 11: 420-428.
4. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545-556.
5. Khatri BO, Pelletier J, Kappos L, et al. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon beta-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relate Disorder 2014; 3: 355-363.
6. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83-89.
7. Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84: 1639-1643.
8. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler 2011; 17: 335-343.
9. Moreira MA, Souza AL, Lana-Peixoto MA, et al. Chemokines in the cerebrospinal fluid of patients with active and stable relapsing-remitting multiple sclerosis. Brazil J Med Biol Res = Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica [et al.] 2006; 39: 441-445.
10. Conductier G, Blondeau N, Guyon A, et al. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 2010; 224: 93-100.
11. Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133: 1082-1093.
12. Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720-1725.
13. Verbeek MM, Notting EA, Faas B, et al. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis. Acta Neurol Scand 2010; 121: 309-314.
14. Lycke JN, Karlsson JE, Andersen O, et al. Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402-404.
15. Axelsson M, Malmestrom C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014; 20: 43-50.
16. Franciotta D, Martino G, Zardini E, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192-198.
17. Mahad DJ, Ransohoff RM,. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 2003; 15: 23-32.
18. Axelsson M, Malmestrom C, Nilsson S, et al. Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis. J Neurol 2011; 258: 882-888.
19. Malmestrom C, Axelsson M, Lycke J, et al. CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J Neuroimmunol 2014; 269: 87-89.
20. Olsson B, Malmestrom C, Basun H, et al. Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials. J Alzheimers Dis 2012; 32: 273-276.
21. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009; 73: 2003-2010.
22. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurology 2011; 69: 292-302.
23. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
24. Kurtzke JF,. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
25. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
26. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914-1922.
27. Rosengren LE, Wikkelso C, Hagberg L,. A sensitive ELISA for glial fibrillary acidic protein: Application in CSF of adults. J Neurosci Methods 1994; 51: 197-204.
28. Paul D, Ge S, Lemire Y, et al. Cell-selective knockout and 3D confocal image analysis reveals separate roles for astrocyte-and endothelial-derived CCL2 in neuroinflammation. J Neuroinflammation 2014; 11: 10.
29. Malmestrom C, Andersson BA, Haghighi S, et al. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: Implications for their possible immunopathogenic roles. J Neuroimmunol 2006; 175: 176-182.
30. Kester MI, Teunissen CE, Crimmins DL, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 2015; 72: 1275-1280.
31. Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res 2010; 1362: 13-22.
32. Portelius E, Zetterberg H, Skillback T, et al. Cerebrospinal fluid neurogranin: Relation to cognition and neurodegeneration in Alzheimer's disease. Brain 2015; 138: 3373-3385.
33. Modvig S, Degn M, Horwitz H, et al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS ONE 2013; 8: e77163.